View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 18, 2020

WHO suspends recruitment of hydroxychloroquine in Solidarity trial again

By Allie Nawrat

The World Health Organization (Who ) has announced it has once again suspended recruitment of the hydroxychloroquine arm of its Covid-19 Solidarity trial.

According to a release, the principal investigators of the trial made this decision because of the results of the  Solidarity Trial, the UK’s RECOVERY trial and a Cochrane review of other evidence.

“Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK’s RCECOVERY trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.”

This decision within two weeks of the Who announcing it was re-starting the recruitment of the hydroxychloroquine arm of  Solidarity trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology